



# Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Fengrui Xu<sup>1,2</sup>, Yang Zhang<sup>3</sup>, Zhanhui Miao<sup>4</sup>, Xiaohua Zeng<sup>5</sup>, Biao Wu<sup>6</sup>, Li Cai<sup>7</sup>, Jinping Liu<sup>8</sup>, Shusen Wang<sup>9</sup>, Xichun Hu<sup>10</sup>, Wenbo Zheng<sup>11</sup>, Zhiyue Chen<sup>12</sup>, Qing Yang<sup>12</sup>, Zefei Jiang<sup>1</sup>

<sup>1</sup>Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China; <sup>2</sup>Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China; <sup>3</sup>Department of Breast Surgery, Liaocheng People's Hospital, Liaocheng 252000, China; <sup>4</sup>Department of Medical Oncology, The First Affiliated Hospital of Xinxiang University, Xinxiang 453100, China; <sup>5</sup>Department of Breast Surgery, Hongqing Cancer Hospital, Chongqing 400030, China; <sup>6</sup>Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China; <sup>7</sup>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China; <sup>8</sup>Department of Breast Surgery, Sichuan Province People's Hospital, Chengdu 610072, China; <sup>9</sup>Department of Medical Oncology, Zhongshan University Cancer Center, Guangzhou 510060, China; <sup>10</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; <sup>11</sup>Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; <sup>12</sup>Department of Research and Development, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 200120, China

Correspondence to: Zefei Jiang. Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing 100071, China. Email: jiangzefei@cscsco.org.cn.

doi: 10.21037/atm-2020-23

View this article at: <http://dx.doi.org/10.21037/atm-2020-23>

Erratum to: Ann Transl Med 2019;7:482.

*Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial*

In the article entitled “Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial” (1), the affiliation of Fengrui Xu should be corrected as follows: <sup>1</sup>Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China; <sup>2</sup>Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China

We regret the errors.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Xu F, Zhang Y, Miao Z, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. *Ann Transl Med* 2019;7:482.

**Cite this article as:** Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. *Ann Transl Med* 2020;8(10):660. doi: 10.21037/atm-2020-23